Abstract
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.
Original language | English (US) |
---|---|
Pages (from-to) | 23-27 |
Number of pages | 5 |
Journal | Current Osteoporosis Reports |
Volume | 8 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2010 |
Keywords
- BMD
- BMP
- Osteoporosis
- PTH
- Sclerostin
- Wnt
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism